# A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia

> **NCT06182592** · PHASE3 · NOT_YET_RECRUITING · sponsor: **CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- High-risk (Secondary) Acute Myeloid Leukemia

## Interventions

- **DRUG:** Liposomal cytarabine-daunorubicin for injection
- **DRUG:** 7+3 (cytarabine and daunorubicin)

## Key facts

- **NCT ID:** NCT06182592
- **Lead sponsor:** CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-01
- **Primary completion:** 2026-02
- **Final completion:** 2026-08
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06182592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06182592, "A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06182592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*